مصري فيت

السلام عليكم ورحمة الله وبركاته نامل ان تكون في اتم صحه وعافيه
مصري فيت

منتدي لعلوم الطب البيطري وما يشملها


    مرض GENITAL HERPES

    شاطر

    admin
    Admin

    المساهمات : 2529
    تاريخ التسجيل : 22/03/2010
    العمر : 56
    الموقع : O.KATTAB@YAHOO.COM

    مرض GENITAL HERPES

    مُساهمة من طرف admin في الأربعاء يونيو 22, 2011 2:44 pm





    ARTICLE TOOLS1-


    [ندعوك للتسجيل في المنتدى أو التعريف بنفسك لمعاينة هذا الرابط][ندعوك للتسجيل في المنتدى أو التعريف بنفسك لمعاينة هذا الرابط][ندعوك للتسجيل في المنتدى أو التعريف بنفسك لمعاينة هذا الرابط][ندعوك للتسجيل في المنتدى أو التعريف بنفسك لمعاينة هذا الرابط][ندعوك للتسجيل في المنتدى أو التعريف بنفسك لمعاينة هذا الرابط]






    The purpose of this descriptive study was to examine
    gender differences in the disease experience of persons who have genital
    herpes. Participants were 60 volunteers (34 females, 26 males) with
    recurrent genital herpes. Their average age was 31.7 years and the
    average length of time since diagnosis was 5.3 years. They completed
    questionnaires that included items about disease characteristics,
    disease stressors, and disease impact. The majority of reported
    stressors related to the consequences of the disease. A wide diversity
    of stressors were described, and results gave evidence of gender
    similarities in the disease experience. Exceptions were that women
    reported experiencing more worry with regard to negative effects on
    future and present health, disruption of daily activity, and disease
    symptoms. Men reported that recurrences last longer. Both disease
    symptoms and the presence of an intimate relationship were related to
    the perceived disease impact. Implications for sensitive interventions
    are discussed.Keywords:


    • Recurrent
      genital herpes;
    • congenital abnormalities;
    • case-control
      design


    Abstract

    Objective.
    To study the possible links between recurrent symptomatic genital
    herpes during pregnancy and risk for congenital abnormalities (CAs). Method.
    The occurrence of prospectively and medically-recorded recurrent
    genital herpes during pregnancy in the mothers of cases with different
    congenital abnormalities and in the mothers of matched controls without
    CAs was compared in the population-based large data set of the Hungarian
    Case-Control Surveillance System of Congenital Abnormalities. Results.
    Of 22,843 cases with CAs, 59 (0.26%) were born to mothers with
    recurrent symptomatic genital herpes, while of 38,151 control newborns
    without CAs, 86 (0.23%) were born to mothers with recurrent genital
    herpes during the study pregnancy (adjusted OR: 1.1, 95% CI: 0.8–1.6).
    Pregnant women with clinically recognised recurrent genital herpes in
    the first trimester of pregnancy are not linked with a higher risk for
    any CAs. Conclusion. Recurrent genital herpes during pregnancy
    does not associate with a higher risk of CAs.Clinical features of genital
    herpes, perceived causes, stress symptoms, treatments, and psychosocial
    factors in 70 young adults as compared to normative data for
    non-patient controls are described. The clinical features of the disease
    were congruent with those of other groups studied. Stress was viewed as
    the major cause of recurrence, headaches the major stress symptom, and
    acyclovir (an antiviral drug), was the major treatment. Statistically
    significant differences were found between scores obtained from the
    sample of young adults with genital herpes on three of four standardized
    psychological instruments when compared with normative data for non
    patient controls. Young adults with genital herpes had a lower self
    concept, more psychopathology, a greater frequency of daily hassles, and
    less intensity of uplifts. No differences were found, however, between
    the two groups in scores on depression.
    Keywords:


    • antenatal;
    • attitudes;
    • herpes;
    • knowledge


    Abstract

    A descriptive survey of knowledge of genital herpes and
    attitudes to testing was conducted among antenatal clinic attendees at
    the Gold Coast Hospital, Australia. The study subjects showed a good
    knowledge of genital herpes, to a level that appears sufficient for an
    informed choice regarding herpes serology testing to be made. A
    preference for testing for genital herpes was suggested. Although
    serological testing is not routinely required, the results of the study
    indicate that discussion of genital herpes should be considered in the
    antenatal clinic setting.
    Human papillomavirus and
    Herpes simplex virus are the most common genital viral infections
    encountered in clinical practice worldwide. We reviewed the literature
    focusing on new and experimental treatment modalities for both
    conditions, based on to the evidence-based data available. The
    modalities evaluated include topical agents such as immune response
    modifiers (imiquimod, resiquimod, and interferon), antivirals
    (penciclovir, cidofovir, and foscarnet), sinecatechins, microbiocidals
    (SPL7013 gel, and PRO 2000 gel), along with experimental
    (oligodeoxynucleotides), immunoprophylactic, and immunotherapeutic
    vaccines.





    Many patients with genital
    herpes will have recurrences, and for some the recurrences may be
    frequent and severe and accompanied by profound psychosexual morbidity.
    Some patients can successfully be managed with
    intermittent courses of oral or topical acyclovir to be used with each
    recurrence. However this treatment is of limited efficacy, and longterm
    acyclovir suppression may be useful. This form of treatment is highly
    successful for patients with frequent recurrences most of whom will have
    no episodes during treatment.
    The optimum
    dosage for commencing acyclovir suppression is 200 mg four times daily,
    and the dose may subsequently be reduced. Some patients can
    successfully be managed on 400 mg twice daily. Treatment should be
    stopped after 1–2 years as there is some evidence of a decrease in the
    frequency of recurrences. Selecting patients for suppression should be
    based on the frequency, severity, and duration of recurrences as well as
    any associated emotional problems. Some patients may recur on
    suppression, usually due to inadequate dosage.
    Many patients with first episode genital herpes
    experience emotional and psychological problems. However these problems
    only continue if patients have recurrences and continued psychological
    support is essential. Long-term acyclovir suppression improves
    psychological wellbeing but is not a substitute for information,
    counselling, and expert psychosexual support.This descriptive study was
    designed to examine the disease experience of persons who have genital
    herpes by identifying the nature and frequency of disease-related
    stressors and coping responses associated with these stressors.
    Participants were 34 women and 26 men who were on average 5.3 years
    postdiagnosis, and experienced a mean of 6.4 recurrences per year.
    Respondents reported a wide range of disease-related
    stressors (M = 7). The category of stressors identified most
    often was related to disease consequences (73.9%), and included
    difficulty with intimate relationships, difficulty with relationships
    involving family and friends, fear of transmission through both sexual
    activity and casual contact, and concern about negative effects on
    health. Respondents tended to use active coping, planning, and
    acceptance more often than passive strategies such as denial.
    Implications for clinical assessment and intervention are discussed.In recent years, it has become
    increasingly clear that genital ulcers from herpes simplex virus (HSV)
    are associated with HIV acquisition. In light of this evolving synergy
    in transmission and the availability of effective antiviral therapy,
    proper diagnosis and management of HSV becomes increasingly important.
    Unfortunately, conventional HSV management is founded on several popular
    misconceptions. Herein, we hope to dispel these common misconceptions
    and expand the current model of herpetic reactivation. By doing so, we
    aimed to unveil potential pitfalls in current herpetic management.Genital herpes is a common,
    distressing infection whose incidence has been underestimated. Recent
    serological surveys, employing type-specific antibody assays, show a
    rising prevalence of previous herpes simplex virus (HSV) type 2
    infections in post-adolescent populations in developed countries; many
    of these infections have been asymptomatic. In some geographical
    locations, HSV-1 infections are a common cause of first episodes. They
    may occur in stable, monogamous relationships and are less likely to
    recur than genital infections caused by HSV-2.
    The clinical features of first episode genital herpes
    show marked individual variation in severity; they tend to be more
    severe in women than in men. Local and distant complications are common
    in immunocompetent individuals and may be life-threatening in those who
    are immunocompromised. The psychological and social consequences which
    result from the life-long infection and its risks of transmission to new
    sexual partners often prove more disabling to affected individuals than
    do the milder physical symptoms associated with recurrent episodes.
    Counselling, support, and patient education are
    essential components of management. Acyclovir is clearly established as
    the first choice therapy in both first and recurrent episodes genital
    herpes. This drug has potent antiviral effect and provides significant
    clinical benefit first episodes. Systemic therapy for initial episodes
    does not prevent either the establishment of latency or the development
    of future recurrences even when used in high or prolonged dosage.
    Episodic treatment of recurrences, with either oral or topical
    acyclovir, requires early patient initiation of therapy to provide
    significant clinical benefit.

      الوقت/التاريخ الآن هو الخميس ديسمبر 14, 2017 6:26 am